Friday, November 22, 2024
HomeTagsTechBio

Tag: TechBio

spot_imgspot_img

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Owkin, the first end-to-end TechBio unicorn that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, has unveiled an innovative drug...

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer,...

SimBioSys Launches TumorSight Plan, A Pioneering Clinical Decision Support for Early-Stage Breast Cancer

TumorSight Plan is the first clinical decision support tool to support more effective provider-patient decision making and individualize surgical planning to right-size care. SimBioSys®, a...

Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development

Caris Discovery™, the therapeutic research arm of Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer, announced a multi-year strategic...

TechBio Unicorn Owkin Teams Up with AWS to Advance Generative AI for Precision Medicine

Owkin, a TechBio that combines the best of human and artificial intelligence to find the right treatment for every patient, announced they are working...

Bayer and Recursion focus research collaboration on Oncology

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

[tds_leads input_placeholder=”Your email address” btn_horiz_align=”content-horiz-center” pp_msg=”SSd2ZSUyMHJlYWQlMjBhbmQlMjBhY2NlcHQlMjB0aGUlMjAlM0NhJTIwaHJlZiUzRCUyMiUyMyUyMiUzRVByaXZhY3klMjBQb2xpY3klM0MlMkZhJTNFLg==” pp_checkbox=”yes” tdc_css=”eyJhbGwiOnsibWFyZ2luLXRvcCI6IjMwIiwibWFyZ2luLWJvdHRvbSI6IjQwIiwiZGlzcGxheSI6IiJ9LCJwb3J0cmFpdCI6eyJtYXJnaW4tdG9wIjoiMTUiLCJtYXJnaW4tYm90dG9tIjoiMjUiLCJkaXNwbGF5IjoiIn0sInBvcnRyYWl0X21heF93aWR0aCI6MTAxOCwicG9ydHJhaXRfbWluX3dpZHRoIjo3NjgsImxhbmRzY2FwZSI6eyJtYXJnaW4tdG9wIjoiMjAiLCJtYXJnaW4tYm90dG9tIjoiMzAiLCJkaXNwbGF5IjoiIn0sImxhbmRzY2FwZV9tYXhfd2lkdGgiOjExNDAsImxhbmRzY2FwZV9taW5fd2lkdGgiOjEwMTksInBob25lIjp7Im1hcmdpbi10b3AiOiIyMCIsImRpc3BsYXkiOiIifSwicGhvbmVfbWF4X3dpZHRoIjo3Njd9″ display=”column” gap=”eyJhbGwiOiIyMCIsInBvcnRyYWl0IjoiMTAiLCJsYW5kc2NhcGUiOiIxNSJ9″ f_msg_font_family=”downtown-sans-serif-font_global” f_input_font_family=”downtown-sans-serif-font_global” f_btn_font_family=”downtown-sans-serif-font_global” f_pp_font_family=”downtown-serif-font_global” f_pp_font_size=”eyJhbGwiOiIxNSIsInBvcnRyYWl0IjoiMTEifQ==” f_btn_font_weight=”700″ f_btn_font_size=”eyJhbGwiOiIxMyIsInBvcnRyYWl0IjoiMTEifQ==” f_btn_font_transform=”uppercase” btn_text=”Unlock All” btn_bg=”#000000″ btn_padd=”eyJhbGwiOiIxOCIsImxhbmRzY2FwZSI6IjE0IiwicG9ydHJhaXQiOiIxNCJ9″ input_padd=”eyJhbGwiOiIxNSIsImxhbmRzY2FwZSI6IjEyIiwicG9ydHJhaXQiOiIxMCJ9″ pp_check_color_a=”#000000″ f_pp_font_weight=”600″ pp_check_square=”#000000″ msg_composer=”” pp_check_color=”rgba(0,0,0,0.56)” msg_succ_radius=”0″ msg_err_radius=”0″ input_border=”1″ f_unsub_font_family=”downtown-sans-serif-font_global” f_msg_font_size=”eyJhbGwiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==” f_input_font_size=”eyJhbGwiOiIxNCIsInBvcnRyYWl0IjoiMTIifQ==” f_input_font_weight=”500″ f_msg_font_weight=”500″ f_unsub_font_weight=”500″]

Must read

spot_img